
Pharma manufacturing 'boom' faces high costs, potential delays
With more than $270 billion in commitments to date, a new wave of pharmaceutical manufacturing is slated to hit the US. At least, that’s what the industry is trying to project. Take Johnson & Johnson's (JNJ) $55 billion over the next four years, …